Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics
Exclusive worldwide license and collaboration agreement to discover, develop and commercialize small molecule drug candidates against several RNA targets.
Partnership will leverage Ribometrix’s RNA-targeting small molecule discovery platform.
Ribometrix to receive $25 million upfront payment and is eligible for potential milestone payments exceeding $1 billion.
DURHAM, N.C. – January 6, 2021 – Ribometrix, Inc., today announced a strategic collaboration with Genentech, a member of the Roche Group, to discover and develop novel RNA-targeted small molecule therapeutics against several targets.
Vertex and Ribometrix Establish Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics
Partnership will leverage Ribometrix’s discovery platform for up to three therapeutic programs
Ribometrix to receive $20 million in upfront payment and Vertex equity investment; potential for additional milestones and royalty payments
BOSTON, Mass. and DURHAM, N.C. – September 30, 2019 – Vertex Pharmaceuticals Incorporated, NASDAQ: VRTX, and RNA therapeutics developer Ribometrix, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases. The collaboration will combine Ribometrix’s proprietary discovery platform for identifying and optimizing small molecule therapeutics that modulate RNA function by targeting three-dimensional (3D) RNA structures with Vertex’s scientific, clinical and regulatory capabilities for up to three therapeutic programs, including one ongoing discovery program from Ribometrix.
Ribometrix Further Expands Leadership with Appointment of Barclay "Buck" Phillips as Chief Operating Officer and Chief Financial Officer
DURHAM, N.C. – August 4, 2020 – Ribometrix, a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases, announced today the appointment of Barclay "Buck" Phillips as chief operating officer and chief financial officer. Mr. Phillips brings more than 25 years of experience in life sciences and venture capital to Ribometrix. Over that period he has served as chief financial officer of three separate NASDAQ-listed biotechnology companies, as a managing director of a biotech focused venture capital fund and as a biotech analyst at a major public mutual fund complex. In addition, Mr. Phillips has served on the board of directors of more than a dozen public or private life sciences companies.
Ribometrix Announces $7.8 Million in New Funding to Advance RNA-Targeting Drug Discovery Platform
Company appoints Flexion Therapeutics CEO Mike Clayman as board chairman
DURHAM, N.C. – September 27, 2019 – Ribometrix, a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases, today announced $7.8 million in additional funding from existing investors, the Dementia Discovery Fund and Illumina Ventures. Ribometrix also announced the appointment of Mike Clayman, M.D., as chairman of the board of directors.
Ribometrix Appoints Industry Veteran John Reardon as Chief Scientific Officer and Expands Management Team
Dr. Reardon to lead strategic development of Ribometrix platform for novel RNA drug discovery
Appointment of two vice presidents to boost expanded research and discovery operations
#Ribometrix is excited to announce the addition of John Reardon, Ph.D., as our new Chief Scientific Officer. John has more than thirty years of experience in the biopharmaceutical industry, with the last twelve spent in operational roles within small, virtual or partially virtual therapeutic-focused companies.
#Ribometrix is excited to announce the addition of Don Hertzog, Ph.D. as our Vice President of Drug Discovery. Dr. Hertzog joins us from HemoShear Therapeutics where he was Head of Chemistry, leading all aspects of chemistry for HemoShear’s drug discovery programs in rare diseases.
#Ribometrix is excited to announce the addition of Bill Janzen as our new VP of Lead Discovery and Research Operations. Mr. Janzen has thirty years of experience in innovative drug discovery and has been a leader in the field of lead generation in academia, start-up ventures and large pharmaceutical companies.
Ribometrix Announces $30 Million Series A Funding
Ribometrix, a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases, announced today that it has completed a $30 million Series A financing to advance its discovery platform and internal pipeline of novel small molecule drugs that directly modulate RNA activity, as well as expand its team and business development activity.
Ribometrix Raises $7.5 Million
Ribometrix, Inc., a biotech company dedicated to discovering and developing small molecule modulators of RNA to treat disease, has raised $7.5 million in seed capital.
Small Molecules Against RNA
The start-up Ribometrix in North Carolina is scouring the three-dimensional, 3D, or tertiary, structures of RNA to find potential targets for small-molecule drugs. “If you’re going after tertiary structures, it looks like any other kind of drug discovery,” says Kevin Weeks, a biochemist at the University of North Carolina in Chapel Hill and founder of Ribometrix. “Just like with protein folding, you can find appropriate clefts and crevices withinRNA to target.” The company is searching for microRNAs and mRNAs associated with cancer, fibrosis, Huntington’s disease and multiple sclerosis. According to Weeks, the company has identified ten targets. “What gets me excited about these small molecules is if you draw structures, they look like normal drugs,” Weeks says. “They don’t look like anything special.” He adds that the company hopes to have multiple clinical leads by 2019....